PCA3 and prostate cancer: Despite the significant interest in ncRNA research in recent years, including the regulatory approval of the ncRNA-based PCA3 assay in early prostate cancer [165], our review suggests that ncRNAs are in fact understudied: only one miRNA, miR-375, was evaluated in more than two papers; moreover, of the four identified articles, three were performed by the same team on patients presenting in the same institution, which potentially limits the generalizability of the results.